The U.S. Food and Drug Administration granted Breakthrough Therapy Designation for Usona Institute‘s psilocybin for the treatment of major depressive disorder (MDD), the organization announced today. According to a release, the designation bolsters Usona’s…

Promega announced today that it will develop its microsatellite instability (MSI) technology for Merck. According to a release, MSI technology may be used to better characterize tumors and guide therapeutic choices for…